Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older.
- You must be willing and able to sign a consent form approved by an ethics review board.
- You must have a solid tumor (cancer) that has been confirmed by lab testing to have a specific genetic change called a KRAS G12D mutation, and the cancer cannot be surgically removed or has spread to other parts of the body.
- Your cancer must be measurable on scans according to standard medical guidelines.
- You must be relatively physically active and able to care for yourself, with only minor limitations on daily activities (this is measured on a standard scale called ECOG, scores 0 or 1).
- Your liver, kidneys, and other organs must be working well enough to participate.
- Your heart must be functioning adequately.
- Any side effects from previous cancer treatments must have mostly resolved before joining.
- You must agree to use highly effective birth control during the trial.
Who may not be able to join:
- You have had a major surgery (other than a diagnostic procedure) within the 4 weeks before the trial starts.
- You have received chemotherapy, targeted therapy, or radiation therapy (other than pain-relieving radiation) within 4 weeks or a certain time based on the medication used — whichever is shorter — before the trial starts, or immunotherapy within 4 weeks before the trial starts.
- You have taken part in another clinical trial using an experimental drug within 4 weeks (or a certain time based on that drug) before this trial starts.
- You have previously been treated with a drug that specifically targets the KRAS G12D mutation.
- You have cancer that has spread to the brain or spinal cord and is causing symptoms, has not been treated, or is getting worse.
- You are unable to swallow pills or oral medications.
- You have a serious, uncontrolled medical condition affecting the blood, kidneys, liver, lungs, heart, gut, mind, skin, immune system, or other body systems (confirm with trial site).
- You are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1 781 292 4204
Australian sites
61 3 9781 5244
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375; Part A: To identify the MTD or MFD; Part B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen; Part C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.; Part C: To identify a recommended dose for subsequent studies of combination dosed VS-7375.; Part D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part C
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.